Concert Pharmaceuticals (Concert Pharmaceuticals) Cash per Share : $3.12 (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Concert Pharmaceuticals's Cash per Share for the quarter that ended in Sep. 2022 was $3.12.

Concert Pharmaceuticals Cash per Share Historical Data

The historical data trend for Concert Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concert Pharmaceuticals Cash per Share Chart

Concert Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash per Share

Get a 7-Day Free Trial

8.78

6.86

4.69

4.14

4.12

Concert Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash per Share	Get a 7-Day Free Trial															3.28	4.12	3.14	3.23	3.12

Concert Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Concert Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2021 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	143.099	/	34.74
	=	4.12

Concert Pharmaceuticals's Cash per Share for the quarter that ended in Sep. 2022 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	149.533	/	47.93
	=	3.12

Concert Pharmaceuticals (NAS:CNCE) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Concert Pharmaceuticals Cash per Share Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421

Website

https://www.concertpharma.com

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

Executives

James V Cassella	officer: Chief Development Officer	2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker	officer: CFO, PFO	175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart	officer: Chief Operating Officer	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie	officer: Chief Legal Officer	CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung	director, officer: Chief Executive Officer	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt	director
Thomas G Auchincloss	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich	director	1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van	director	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland	director	C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett	director	C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger	director	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511